Evaluation Of Apolipoprotein B In Type li Diabetes Mellitus Patients
Keywords:
ApoB, lipid profile, HbA1c, T2DM.Abstract
According to statistics about 415 million people in the world suffer from this dangerous disease, Type 2 DM accounts for over 90% of DM cases. So, we evaluated some parameters that may affect T2DM. The aim of the present study is to find the relation of Apo B, with the T2DM condition and to evaluate how apo B change affects the T2DM. In case-control study the 180 serum and whole blood sample which collected from non-diabetic (n = 60) and T2DM (n = 120) persons were estimated for Apo B by the use of ELISA technique and the lipid profile was estimated by using mindray BS-430 and HbA1c by GH-900 Plus device. Whole blood was collected via vein puncture. We were collecting 180 sample of whole blood and serum from the diabetes center which divided into two groups 60 non diabetic and 120 diabetic persons. In present study showed significantly (P<0.001) increase in T2DM group compare to non-diabetic group in serum Apo B and HbA1c, FBS, TG, Cholesterol, LDL. This study was showed a significant (P <0.05) positive correlation between Apo B, HbA1c and lipid profile. From this study can be concluded that Apo B and lipid profile changes affect insulin resistance and as a result T2DM. And can be concluded that Apo B can be regarded as a marker of T2DM.
Downloads
References
Mana, S. T., Mahdi, D. S., & Altemimi, M. T. (2022). The Prediction of
Micro-and Macrovascular Complications in Individuals with T2DM
with Different Risk Factors in Iraq. Biomedical and Pharmacology
Journal, 15(3), 1769-1782.
Pathan, S. B., Jawade, P., & Laila, P. (2020). Correlation of Serum Urea
and Serum Creatinine in Diabetics patients and normal
individuals. Int J Clin Biochem Res, 7(1).
Chadt, A., & Al-Hasani, H. (2020). Glucose transporters in adipose tissue,
liver, and skeletal muscle in metabolic health and disease. Pflugers
Archiv-European Journal of Physiology, 472, 1273-1298.
Liu, K., Jin, X., Zhang, X., Lian, H., & Ye, J. (2022). The mechanisms of
nucleotide actions in insulin resistance. Journal of Genetics and
Genomics, 49(4), 299-307.
Wesling, M., & D’Souza, J. J. (2022). Diabetes: howto manage overweight
and obesity in type 2 diabetes mellitus. Drugs in Context, 11.
Rifai, N. (2017). Tietz textbook of clinical chemistry and molecular
diagnostics-e-book. Elsevier Health Sciences.
Shetty, S. S., & Kumari, S. (2021). Fatty acids and their role in type-2
diabetes. Experimental and therapeutic medicine, 22(1), 1-6.
Haile, K., & Timerga, A. (2020). Dyslipidemia and its associated risk
factors among adult type-2 diabetic patients at Jimma University
Medical Center, Jimma, Southwest Ethiopia. Diabetes, metabolic
syndrome and obesity: targets and therapy, 13, 4589.
Salami, F., N. Tamura, R., Elding Larsson, H., Lernmark, A., Torn, C., &
TEDDY Study Group. (2021). Complete blood counts with red blood
cell determinants associate with reduced beta cell function in
seroconverted Swedish TEDDY children. Endocrinology, Diabetes &
Metabolism, 4(3), e00251.
Lackner, L, Weber, B., Knecht, D., Horst, K., Relja, B., Gebhard, F., ... &
TREAT research group. (2020). Cardiac glucose and fatty acid
transport after experimental mono-and polytrauma. Shock, 53(5),
-629.
Pohanka, M. (2021). Glycated hemoglobin and methods for its point of
care testing. Biosensors, 11(3), 70.
Pelham, J. H., Hanks, L., Aslibekyan, S., Dowla, S., & Ashraf, A. P. (2019).
Higher hemoglobin A1C and atherogenic lipoprotein profiles in
children and adolescents with type 2 diabetes mellitus. Journal of
clinical & translational endocrinology, 15, 30-34.
Sunil, B., & Ashraf, A. P. (2020). Dyslipidemia in pediatric type 2 diabetes
mellitus. Current diabetes reports, 20, 1-9.Fonseca, L., Paredes, S., Ramos, H., Oliveira, J. C., & Palma, I. (2020).
Apolipoprotein B and non-high-density lipoprotein cholesterol
reveal a high atherogenicity in individuals with type 2 diabetes and
controlled low-density lipoprotein-cholesterol. Lipids in Health and
Disease, 19(1), 1-9.
Feingold, K. R. (2020). Obesity and dyslipidemia. Endotext [Internet].
Son, N. E. (2019). Influence of ferritin levels and inflammatory markers
on HbAlc in the Type 2 Diabetes mellitus patients. Pakistan journal
of medical sciences, 35(4), 1030.
Lorenzatti, A. J., Monsalvo, M. L., Lopez, J. A. G., Wang, H., & Rosenson,
R.S. (2021). Effects of evolocumab in individuals with type 2 diabetes
with and without atherogenic dyslipidemia: An analysis from
BANTING and BERSON. Cardiovascular Diabetology, 20(1), 1-14.
Namani, R. R. G., & Laxmi Narayana Sripuram, S. (2022). A Study on
Serum Myeloperoxidase, Apolipoprotein B and Glycated
Hemoglobin Levels in Type 2 Diabetes Mellitus. European journal of
Molecular & Clinical Medicine, 9(3), 864-870.
Li, Q., Zhao, M., Wang, Y., Zhong, F., Liu, J., Gao, L., & Zhao, J. (2021).
Associations between serum free fatty acid levels and incident
diabetes in a 3-year cohort study. Diabetes, MetabolicSyndrome and
Obesity: Targets and Therapy, 2743-2751.
Naeini, Z., Abaj, F., Esmaeily, Z., Alvandi, E., Rafiee, M., & Koohdani, F.
(2023). A Nutrigenetic Approach to Investigate ApoB EcoRi
Polymorphism-Dietary Acid Load Interactions on Lipid and
Anthropometric-Related Outcomes in Adults with Dyslipidemic
Type 2 Diabetes. Lifestyle Genomics, 16, 61-72.
Ye, R. Z., Richard, G., Gevry, N., Tchernof, A., &Carpentier, A. C. (2022).
Fat cell size: measurement methods, pathophysiological origins, and
relationships with metabolic dysregulations. Endocrine
reviews, 43(1), 35-60.
Parra-Peralbo, E., Talamillo, A., & Barrio, R. (2021). Origin and
development of the adipose tissue, a key organ in physiology and
disease. Frontiers in Cell and Developmental Biology, 9, 3636.
Feingold, K. R. (2021). Introduction to lipids and lipoproteins, endotext
[internet].
Downloads
Published
Issue
Section
License
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
